mRNA and Gene Therapy: Why Do Raw Materials Matter?

Why is demand for mRNA and gene therapy materials attracting attention?

An October 18 IndexBox outlook identifies mRNA vaccines, gene therapies, and gene editing as drivers of demand for nucleotides, plasmid DNA, and other nucleic acid materials. These supplies support different stages of medicine development, from laboratory experiments to commercial production. The report is a commercial market forecast; its projections do not demonstrate clinical benefit or guarantee future approvals. [IndexBox market outlook](https://www.indexbox.io/blog/nucleic-acid-raw-materials-market-forecast-to-2035-growth-accelerates-on-mrna-vaccine-and-gene-therapy-demand/)

Existing approvals illustrate why this manufacturing infrastructure matters. On May 31, 2024, the FDA approved the mRNA vaccine mRESVIA to prevent lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 and older. That historical approval demonstrated a commercial application of mRNA vaccination beyond COVID-19. [FDA approval announcement](https://www.fda.gov/news-events/press-announcements/fda-roundup-may-31-2024)

Gene editing presents a different production challenge. In December 2023, Casgevy became the first FDA-approved treatment using CRISPR/Cas9. Its manufacturing process modifies a patient's blood stem cells outside the body before they are returned by infusion. This individualized cell treatment and a manufactured vaccine require distinct production systems, even though both belong to the broader field of medicines involving genetic information. [FDA gene therapy announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease)

How does raw material quality affect mRNA vaccine manufacturing?

Manufacturers produce mRNA using a DNA template, nucleotide building blocks, and enzymes. Lipid nanoparticles help protect the resulting RNA and deliver it into cells. WHO guidance calls for information about the source, quality, stability, and role of these materials, including the lipids. Suppliers also need qualification through the manufacturer's quality system. [WHO manufacturing guidance](https://cdn.who.int/media/docs/default-source/biologicals/vaccine-standardization/annex-3---mrna-vaccines_who_trs_1039_web-2.pdf)

Quality oversight continues throughout production. WHO describes controls for impurities, tests of the intended genetic sequence, and manufacturing validation to demonstrate consistent output. These checks explain why expanding supply involves more than purchasing larger quantities of ingredients: manufacturers must show that their processes reliably produce material suitable for human use. [WHO quality-control guidance](https://cdn.who.int/media/docs/default-source/biologicals/vaccine-standardization/annex-3---mrna-vaccines_who_trs_1039_web-2.pdf)

Could stronger material supplies help treatments reach patients sooner?

A reasonable implication of the IndexBox outlook is that dependable supplies could reduce one source of disruption as developers expand production. The report does not establish how many patients would benefit or how much waiting times might change. For investigational gene therapies, FDA guidance describes the manufacturing information needed to support product safety, identity, quality, purity, and potency. Expanding production therefore involves documenting what the product is and how consistently it can be made. [FDA investigational gene therapy guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug)

Manufacturing changes also require careful evaluation. The FDA's July 2023 draft guidance discusses comparability studies that assess how changes affect cell and gene therapy product quality. This draft is nonbinding and is not final guidance, but it explains an important scientific challenge: a revised process must be assessed for its effect on the resulting medicine. [FDA draft comparability guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-changes-and-comparability-human-cellular-and-gene-therapy-products)

Delivery can remain demanding even after a treatment is manufactured. The FDA's original Casgevy announcement describes stem-cell collection, high-dose chemotherapy before infusion, and long-term follow-up. For such treatments, material availability is one component of access alongside specialized care. A growing supplier market alone cannot establish that treatment will become simpler or less expensive. [FDA treatment overview](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease)